Glaukos Corporation

NYSE:GKOS

Medical - Devices

Healthcare
$233.08 -0.14%

-$0.18 today

Market cap
$13.80B
Beta
0.81
P/E (TTM)
-39.0
EPS (TTM)
-$3.26
52W Low $73.16High $148.11

Volume 1.12M

Average 0.94M

GKOS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Glaukos CorporationNYSE: GKOS

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $116.06M rose 39.2% year over year, ahead of the +34.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 24.9% from the prior quarter. Over 3 fiscal years it compounded at +19.5% a year.

Context

  • Selling, general & admin amounted to 64.9% of revenue in FY2025, down 3.6 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 11 analysts of $521.1M (+58.2%) for the fiscal year ending Dec 2026, a step up from the +25.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$116.06M+24.9% QoQ
Last fiscal yearDec 2025
$329.34M+25.3% YoY
LTMJun 2026
$386.7M+34.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.2%+35.2%-4.0 pp
1 year+25.3%+58.2%+32.9 pp
3-year CAGR+19.5%+37.9%+18.4 pp
5-year CAGR+29.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
329.34M USD
Year-over-year change
+25.3%
4-year CAGR
+16.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How GKOS compares with its peers on the latest reported figures

  • GKOS's LTM Jun 2026 selling, general & admin of $386.7M is the 3rd highest of the 9 companies compared; the peer median is $120.13M.
  • Its year-over-year change of +34.7% is the highest of 8, against a peer median of +1.8%.
  • Selling, general & admin amounts to 63.1% of revenue for GKOS, versus a peer median of 90.9%.
GKOS Competitors Peer median
Selling, General & Admin for GKOS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALCAlcon Inc.LTM Sep 2026$3.64B +8.6%+4.0%33.3%
BLCOBausch + Lomb CorporationLTM Jun 2026$2.22B +1.8%+14.8%41.8%
GKOSGlaukos CorporationLTM Jun 2026$386.7M +34.7%+19.5%63.1%
STAASTAAR Surgical CompanyLTM Apr 2026$177.31M -11.1%+9.5%61.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026$124.38M +14.7%+17.9%239.0%
RXSTRxSight, Inc.LTM Mar 2026$115.87M +8.5%+24.3%90.9%
SGHTSight Sciences, Inc.LTM Mar 2026$91.48M -7.4%-9.4%115.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$53.04M +1.3%-5.0%696.5%
SGPSpyGlass Pharma, Inc. Common StockFY2025$12.2M ———
Peer median (excluding GKOS) $120.13M+1.8%+9.5%90.9%

Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue294.01M282.86M314.71M383.48M507.44M
Cost of Revenue66.63M68.98M75.58M94.03M114.23M
Gross Profit227.38M213.88M239.14M289.45M393.22M
Gross Margin77.3%75.6%76.0%75.5%77.5%
Research & Development101M123.27M138.77M136.43M150.61M
Selling, General & Admin179.26M192.93M224.07M262.85M329.34M
Operating Expenses260.26M296.2M367.84M411.82M479.95M
Depreciation & Amortization34.42M35.95M37.98M39.92M42.35M
EBITDA(1.47M)(48.76M)(82.12M)(95.64M)(146.06M)
EBITDA Margin-0.5%-17.2%-26.1%-24.9%-28.8%
Operating Income(32.87M)(82.31M)(128.7M)(122.37M)(86.73M)
Operating Margin-11.2%-29.1%-40.9%-31.9%-17.1%
Interest Income1.29M2.38M9.16M11.11M10.71M
Interest Expense13.37M13.72M13.63M10.04M4.64M
Other Income / Expenses(16.4M)(16.12M)(5.03M)(23.24M)(106.31M)
Income Before Tax(49.27M)(98.43M)(133.73M)(145.6M)(193.04M)
Pre-Tax Margin-16.8%-34.8%-42.5%-38.0%-38.0%
Income Tax Expense326K766K934K771K(5.35M)
Net Income(49.59M)(99.2M)(134.66M)(146.37M)(187.69M)
Net Margin-16.9%-35.1%-42.8%-38.2%-37.0%
EPS (Basic)(1.07)(2.09)(2.78)(2.77)(3.28)
EPS (Diluted)(1.07)(2.09)(2.78)(2.77)(3.28)
Weighted Avg Shares46.42M47.44M48.43M52.76M57.19M
Weighted Avg Shares (Diluted)46.42M47.44M48.43M52.76M57.19M

Glaukos Corporation

NYSE:GKOS

Intrinsic Alpha fair value

Locked

Current Price

$233.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.